Cognitive Effects of Immunomodulatory Drugs in MS

Sharon Lynch, MD

Status: Completed

Conditions: Multiple Sclerosis

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00229502

10066

Details and patient eligibility

About

The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Full description

In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Enrollment: 96 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diagnosis of RRMS for at least one year,
• Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
• Visual Acuity is 20/50 or better,
• patient has four color vision,
• Must have at least a high school education

Exclusion criteria

• History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS,
• currently taking immunosuppressant medication,
• resides greater than 200 miles from the study site

Trial design

96 participants in 4 patient groups

1

Description:

Subjects receiving Avonex

2

Description:

Subjects receiving Rebif

3

Description:

Subjects receiving Copaxone

4

Description:

Healthy controls